Pancreatic cancer in people with HIV: a case-control study.

IF 2.9 3区医学 Q3 IMMUNOLOGY

JAIDS Journal of Acquired Immune Deficiency Syndromes Pub Date : 2024-12-20 DOI:10.1097/QAI.0000000000003585

Sylvain Chawki, Gwenn Hamet, Alexandre Brun, Nelson Lourenco, Olivier Bouchaud, Julie Bottero, Pierre Sellier, Jean-Michel Molina

{"title":"Pancreatic cancer in people with HIV: a case-control study.","authors":"Sylvain Chawki, Gwenn Hamet, Alexandre Brun, Nelson Lourenco, Olivier Bouchaud, Julie Bottero, Pierre Sellier, Jean-Michel Molina","doi":"10.1097/QAI.0000000000003585","DOIUrl":null,"url":null,"abstract":"Background: We aimed to estimate the incidence and to assess the risks factors associated with pancreatic cancer (PC) in people with HIV (PWH).Setting: We used electronic medical record data from 2009 to 2020 available in the COREVIH Ile-de-France Est database of PWH treated in Paris' public hospitals.Methods: We analyzed data on patient demographics, treatment history, and immuno-virologic status. A case-control study was designed, each case (PWH and PC) was matched on age, gender and duration of HIV infection to four controls (PWH without PC).Results: Twenty-four cases were identified from the database, with an incidence of PC estimated at 28 cases (95%CI [19-43]) per 100,000 persons-year. The median age was 57 years (IQR [51-68]) at cancer diagnosis. Twenty-one cases were male (88%). Median CD4+ T cell count at PC diagnosis was 587/mm3 (IQR [317-748]) and the nadir CD4+ T cell count was 194 (IQR [98-380]). Twenty cases (91%) had a suppressed HIV replication at PC diagnosis. Twelve patients (50%) had metastasis on diagnosis. Median time to death after cancer diagnosis was 11 months [IQR 1-19]. Twenty-two cases were matched with 88 controls. There was no statistically significant risk factors for PC identified in our analysis.Conclusion: Pancreatic cancer remains rare in PWH and is associated with a severe prognosis at a relatively young age. Further studies are needed to identify risk factors associated with pancreatic cancer development in people with HIV.","PeriodicalId":14588,"journal":{"name":"JAIDS Journal of Acquired Immune Deficiency Syndromes","volume":" ","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAIDS Journal of Acquired Immune Deficiency Syndromes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/QAI.0000000000003585","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: We aimed to estimate the incidence and to assess the risks factors associated with pancreatic cancer (PC) in people with HIV (PWH).

Setting: We used electronic medical record data from 2009 to 2020 available in the COREVIH Ile-de-France Est database of PWH treated in Paris' public hospitals.

Methods: We analyzed data on patient demographics, treatment history, and immuno-virologic status. A case-control study was designed, each case (PWH and PC) was matched on age, gender and duration of HIV infection to four controls (PWH without PC).

Results: Twenty-four cases were identified from the database, with an incidence of PC estimated at 28 cases (95%CI [19-43]) per 100,000 persons-year. The median age was 57 years (IQR [51-68]) at cancer diagnosis. Twenty-one cases were male (88%). Median CD4+ T cell count at PC diagnosis was 587/mm3 (IQR [317-748]) and the nadir CD4+ T cell count was 194 (IQR [98-380]). Twenty cases (91%) had a suppressed HIV replication at PC diagnosis. Twelve patients (50%) had metastasis on diagnosis. Median time to death after cancer diagnosis was 11 months [IQR 1-19]. Twenty-two cases were matched with 88 controls. There was no statistically significant risk factors for PC identified in our analysis.

Conclusion: Pancreatic cancer remains rare in PWH and is associated with a severe prognosis at a relatively young age. Further studies are needed to identify risk factors associated with pancreatic cancer development in people with HIV.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

JAIDS Journal of Acquired Immune Deficiency Syndromes 医学-传染病学

CiteScore

5.80

自引率

5.60%

发文量

490

审稿时长

3-6 weeks

期刊介绍： JAIDS: Journal of Acquired Immune Deficiency Syndromes seeks to end the HIV epidemic by presenting important new science across all disciplines that advance our understanding of the biology, treatment and prevention of HIV infection worldwide. JAIDS: Journal of Acquired Immune Deficiency Syndromes is the trusted, interdisciplinary resource for HIV- and AIDS-related information with a strong focus on basic and translational science, clinical science, and epidemiology and prevention. Co-edited by the foremost leaders in clinical virology, molecular biology, and epidemiology, JAIDS publishes vital information on the advances in diagnosis and treatment of HIV infections, as well as the latest research in the development of therapeutics and vaccine approaches. This ground-breaking journal brings together rigorously peer-reviewed articles, reviews of current research, results of clinical trials, and epidemiologic reports from around the world.